MRK Stock Recent News
MRK LATEST HEADLINES
Merck (MRK) closed the most recent trading day at $78.83, moving 1.05% from the previous trading session.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--ACIP Recommends Merck's ENFLONSIA for Prevention of RSV in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season.
Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.
Health and Human Services Secretary Robert F. Kennedy Jr.'s revamped government panel of vaccine advisors recommended the use of Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus.
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest news from the CDC.
An advisory panel of the U.S. Centers for Disease Control and Prevention on Thursday recommended the use of Merck's respiratory syncytial virus therapy, Enflonsia, for infants 8 months or younger, whose mother did not receive a preventive shot during pregnancy.
The S&P 500 flirted with bear-market territory earlier this year. Although it has mostly recovered, plenty of companies are still dealing with issues that have led to poor performances.
MRK breaks above its 50-day average but near-term headwinds and weak China sales challenge the bullish case.
Merck's Winrevair meets goal in a phase III study in newly diagnosed PAH patients, showing strong efficacy.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Investor Event to Highlight Advancing Research Pipeline for HIV Treatment and Prevention.